|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Client-level predictors of treatment engagement,outcome and dropout:moving beyond demographics显示文摘Background Despite the availability of evidence-based treatments for posttraumatic stress disorder(PTSD),significant heterogeneity in the effectiveness of PTSD treatment persists,especially in community settings.Client demographics used to understand this variability in treatment outcome and dropout have yielded mixed results.Despite increasing evidence for the importance of attending to treatment engagement in community settings,few studies have explored client-level predictors.Aim The purpose of this study is to explore client-level predictors of treatment outcome and dropout beyond client demographics,and to identify client-level predictors of treatment engagement in community settings.Method Secondary data analysis was conducted with data collected as part of an implementation-effectiveness hybrid study of cognitive processing therapy(CPT)for PTSD in a diverse community healthcentre.Providers(n=19)treated(n=52)clients as part of their routine clinical care.Non-demographic client-level predictors included barriers to treatment,quality of life,session-level language and employment history assessed at baseline.Treatment engagement included number of weeks in the study,number of sessions with repeated CPT content,number of unique CPT sessions attended,frequency of session attendance and consistency of session attendance.Results Results showed language as a significant predictor of treatment engagement.There were significant differences between Spanish and English-speaking clients,with the former having a tendency to repeat more session content than the latter(β=1.4 sessions,p=0.003),and also less likely to attend treatment frequently(r=0.62,p=0.009)and consistently(r=0.57,p=0.027)if high logistical and financial barriers were endorsed.Irrespective of language,clients who reported high quality of life at baseline were less likely to repeat CPT session content(β=-0.3,p=0.04),and those with increased baseline barriers to treatment had deceleration in PTSD symptom improvement over time(β=-0.62,p<0.05).In terms of treatment engagement moderators impacting treatment outcome,clients who repeated more session content were more likely to complete treatment(0R=1.84,p=0.037).Conclusion Identification of client-level predictors of treatment engagement,outcome and dropout is essential to optimise treatment,particularly in community settings. | Soo-jeong Youn Margaret-Anne Mackintosh Shannon Wiltsey Stirman Kay lie A Patrick Yesenia Aguilar Silvan Anna D Bartuska Derri L Shtasel Luana Marques | 2019 | General Psychiatry2019，32，6： | 2 |
| 2 | Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib显示文摘Background:Cancer-associated fibroblasts(CAFs)play an important role in the induction of chemo-resistance.This study aimed to clarify the mechanism underlying CAF-mediated resistance to two tyrosine kinase inhibitors(TKIs),sorafenib and lenvatinib,and to identify a novel therapeutic target for overcoming TKI resistance in hepatocellular carcinoma(HCC).Methods:We performed a systematic integrative analysis of publicly available gene expression datasets and whole-transcriptome sequencing data from 9 pairs of CAFs and para-cancer fibroblasts isolated from human HCC and para-tumor tissues,respectively,to identify key molecules that might induce resistance to TKIs.We then performed in vitro and in vivo experiments to validate selected targets and related mechanisms.The associations of plasma secreted phosphoprotein 1(SPP1)expression levels before sorafenib/lenvatinib treatment with progression-free survival(PFS)and overall survival(OS)of 54 patients with advanced HCC were evaluated using Kaplan-Meier and Cox regression analysis.Results:Bioinformatic analysis identified CAF-derived SPP1 as a candidate molecule driving TKI resistance.SPP1 inhibitors reversed CAF-induced TKI resistance in vitro and in vivo.CAF-derived SPP1 activated rapidly accelerated fibrosarcoma(RAF)/mitogen-activated protein kinase(MAPK)and phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)through the integrin-protein kinase C-alpha(PKCα)signaling pathway and promoted epithelial-to-mesenchymal transition(EMT).A high plasma SPP1 level before TKI treatment was identified as an independent predictor of poor PFS(P=0.026)and OS(P=0.047)in patients with advanced HCC after TKI treatment.Conclusions:CAF-derived SPP1 enhances TKI resistance in HCC via bypass activation of oncogenic signals and EMT promotion.Its inhibition represents a promising therapeutic strategy against TKI resistance inHCC.Moreover,plasma SPP1 level before TKI treatment represents a potential biomarker for treatment response prediction. | JungWoo Eun Jung Hwan Yoon Hye Ri Ahn Seokhwi Kim Young Bae Kim Su Bin Lim Won Park TaeWook Kang Geum Ok Baek Moon Gyeong Yoon Ju A Son Ji HyangWeon Soon Sun Kim Hyo Jung Cho Jae Youn Cheong | 2023 | Cancer Communications2023，43，4： | 2 |
| 3 | Dual module based maximum power point tracking control of photo- voltaic systems显示文摘 | JOUNG HU P JUN YOUN A BO HYUNG C | 2006 | IEEE Trans on Industrial Electronics2006，53，4： | 1 |
| 4 | Phase 2 study of proteasome inhibitor bortezomib in relapsed or refractory B-cell nonHodgkin's lymphoma显示文摘 | Goy A Younes A Melaughlin P | 2005 | J Clin Oncol2005，23，4： | 1 |
| 5 | CD30-targeted antibody therapy显示文摘 | Younes A | 2011 | Curr OpinOncol2011，23，6： | 1 |
| 6 | Skeletal muscle regulates extracellular potassium显示文摘 | MCDONOUGH A A THOMPSON C B YOUN J H | 2002 | American Journal of Physiology:Renal Physiology2002，282，6： | 1 |
| 7 | A parameters design approach to improve product quality and equipment performance in hot rolling显示文摘 | Mohammad A Younes M Shahtout R | 2006 | Journal of Materials Processing Technology2006，171，1： | 1 |
| 8 | Phase relations and dielectric properties in the Bi2O3-ZnO-Ta2O5 system显示文摘 | YOUN H J SOGABE T RANDALL C A | 2001 | J Am Ceram Soc2001，84，11： | 1 |
| 9 | A pilot study of rituximab in patients with recurrent,classic Hodgkin disease显示文摘 | Younes A Romaguera J Hagemeister F | 2003 | Cancer2003，98，： | 1 |
| 10 | Dieletric properties of BiO3-ZnO-Ta2O5 pyrochlore and zirconnolite structure ceramics显示文摘 | Chen A Zhi Y Youn H J | 2003 | Appl Phys Lett2003，82，21： | 1 |
| 11 | Microbio- ta restoration: natural and supplemented recovery of human microbial communities显示文摘 | REID G YOUNES J A VAN DER MEI H C | 2011 | Nat Rev Microbiol2011，9，1： | 1 |
| 12 | Brentuximab vedotin (SGN-35) for relapsed CD30-poskive lymphomas显示文摘 | Younes A Bartlett N L Leonard J P | 2010 | N Engl J Med2010，363，19： | 1 |
| 13 | Ascorbic acid reduces blood pressure and arterial stifness in type 2 diabetes显示文摘 | Mullan B A Youns L S Fee H | 2002 | Hypertension2002，40，： | 1 |
| 14 | Phase Ⅱ study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma 显示文摘 | GOY A YOUNES A MCLAUGHLIN P | 2005 | J Clin Oncol2005，23，： | 1 |
| 15 | Novel treatment stragtegies for patients with relapsed classical Hodgkin lymphoma 显示文摘 | Jona A Younes A | 2010 | Blood Rev2010，24，6： | 1 |
| 16 | Effect of pore size and aluminium content on the production of linear alkylbenzenes over HY, H-ZSM-5 and H-ZSM-12 zeolites; alkylation of benzene with 1-dodecene显示文摘 | Dufaux M Younes B T | 1994 | Appl Catal A: General1994，114，： | 1 |
| 17 | Heat shock protein-based cancer vaccines 显示文摘 | Oki Y Younes A | 2004 | Expert Rev Vaccines2004，3，4： | 1 |
| 18 | Status of antioxidant enzyme: glutathione peroxidase and total polyphenol level in plasma of Tunisian patients suffering from colorectal and gastric cancer: interaction with clinical outcome显示文摘 | Baroudi O Younes S B Mezlini A | 2013 | Med Oncol2013，30，4： | 1 |
| 19 | Semi-active suspension with adaptive capability显示文摘 | YOUN I HAC A | 1995 | Journal of Sound and Vibration1995，180，3： | 1 |
| 20 | NOX4 as the major catalytic component of an endothelial NAD(P)H oxidase显示文摘 | Tetsuro A Takanari K Hiroaki O Teruaki I Youn HH Junichi T | 2004 | Circulation2004，109，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员